Incretin mimetics as emerging treatments for type 2 diabetes (Q35962037)

11 August 2017

1 reference

title

Incretin mimetics as emerging treatments for type 2 diabetes (English)

1 reference

11 August 2017

0 references

Scott V Joy

1

1 reference

11 August 2017

Philip T Rodgers

series ordinal

2

1 reference

11 August 2017

Ann C Scates

series ordinal

3

1 reference

11 August 2017

language of work or name

English

0 references

publication date

23 November 2004

1 reference

Annals of Pharmacotherapy

11 August 2017

published in

1 reference

11 August 2017

volume

39

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

110-118

1 reference

Insulin versus insulin plus sulfonylureas in type 2 diabetic patients with secondary failure to sulfonylureas

11 August 2017

cites work

1 reference

Lilly Lecture 1994. The beta-cell in diabetes: from molecular genetics to clinical research

21 January 2018

1 reference

New developments in the incretin concept

21 January 2018

1 reference

Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis

21 January 2018

1 reference

Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice

21 January 2018

1 reference

Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells

21 January 2018

1 reference

Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1.

21 January 2018

1 reference

Glucagon and regulation of glucose metabolism

21 January 2018

1 reference

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

21 January 2018

1 reference

Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable

21 January 2018

1 reference

Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor

21 January 2018

1 reference

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

21 January 2018

1 reference

Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes.

21 January 2018

1 reference

21 January 2018

1 reference

Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients

21 January 2018

1 reference

Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.

21 January 2018

1 reference

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

21 January 2018

1 reference

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

21 January 2018

1 reference

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

21 January 2018

1 reference

In vitro cultivation of human islets from expanded ductal tissue

21 January 2018

1 reference

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

21 January 2018

1 reference

Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese rats

21 January 2018

1 reference

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans

21 January 2018

1 reference

Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans

21 January 2018

1 reference

Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment

21 January 2018

1 reference

Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet

21 January 2018

1 reference

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

21 January 2018

1 reference

Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro

21 January 2018

1 reference

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

21 January 2018

1 reference

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

21 January 2018

1 reference

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

21 January 2018

1 reference

The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes

21 January 2018

1 reference

Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes

21 January 2018

1 reference

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

21 January 2018

1 reference

NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs

21 January 2018

1 reference

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

21 January 2018

1 reference

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose

21 January 2018

1 reference

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

21 January 2018

1 reference

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

21 January 2018

1 reference

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

Non-linkage of the glucagon-like peptide 1 receptor gene with maturity onset diabetes of the young

21 January 2018

1 reference

GLP-1 does not acutely affect insulin sensitivity in healthy man

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1E245

1 reference

11 August 2017

1 reference